FRM
CRVS icon

Fox Run Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Fox Run Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Buy
+18,055
New +$251K 0.04% 712
2026
Q1 		– Sell
-11,220
Closed -$86.4K – 951
2025
Q4 		$86.4K Buy
+11,220
New +$88.5K 0.01% 859

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fox Run Management's CRVS Position: Q2 2026 in Review

Fox Run Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 18,055 shares worth $270K. The stake represents 0.04% of the portfolio and ranks #712 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CRVS as recently as Q4 2025.

Fox Run Management first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Fox Run Management held 18,055 shares of Corvus Pharmaceuticals worth $270K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Fox Run Management position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.04% of Fox Run Management's portfolio in Q2 2026, its #712 holding.
  • Fox Run Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.